{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:45:11Z","timestamp":1790142311429,"version":"4.0.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The course of multiple myeloma (MM) from initial diagnosis to a relapsed\/refractory state is characterized by acquisition of drug resistance as well as progressive immunologic dysfunction. Despite this, however, a number of novel therapies that work in part or solely via immune stimulation are in development for MM, with promising early clinical results. Several new whole-cell or multiepitope vaccine approaches are demonstrating immunologic efficacy in smoldering MM or as posttherapy consolidation, with trials ongoing to see whether this translates into delayed progression or elimination of minimal residual disease. Programmed death-1 (PD-1)\/programmed death ligand-1 (PD-L1) inhibition in combination with immunomodulatory drugs demonstrated excessive toxicity in randomized trials; however, antibodies targeting PD-1\/PD-L1 and other checkpoint molecules continue to be explored in combination with tumor-targeted antibodies and other T cell\u2013directed therapies. B-cell maturation antigen (BCMA) has emerged as the next big antigen target, with multiple BCMA-specific antibody-drug conjugates (ADCs) and T cell\u2013directed bispecific antibodies\/bispecific therapeutic engagers (BiTEs) entering the clinic. In initial trials, the ADC GSK2857916 and the BiTE AMG 420 have demonstrated high response rates in relapsed\/refractory patients, with depth and durability of responses that may end up rivaling chimeric antigen receptor T-cell therapies. These agents have unique toxicities that require close monitoring, but they are moving forward in larger registration studies and in combination with standard MM agents. Additional ADCs and bispecific antibodies targeting BCMA and other surface antigens (eg, CD38, CD46, CD48, FcRH5, and G protein\u2013coupled receptor, class C group 5 member D) are moving forward in phase 1 trials and may provide even more options for MM patients.<\/jats:p>","DOI":"10.1182\/hematology.2019000068","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:17:05Z","timestamp":1575645425000},"page":"266-272","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Myeloma: next generation immunotherapy"],"prefix":"10.1182","volume":"2019","author":[{"given":"Adam D.","family":"Cohen","sequence":"first","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019120610114119300_B1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12185-018-2405-7","article-title":"Immunopathogenesis and immunotherapy of multiple myeloma","volume":"107","author":"Tamura","year":"2018","journal-title":"Int J Hematol"},{"issue":"5","key":"2019120610114119300_B2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","article-title":"Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells","volume":"20","author":"Rapoport","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019120610114119300_B3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2010-08-299396","article-title":"Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma","volume":"117","author":"Rapoport","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2019120610114119300_B4","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4548.4548","article-title":"Randomized phase II trial of combination idiotype vaccine and anti-CD3\/anti-CD28 costimulated autologous T cells in patients with multiple myeloma post-autotransplantation","volume":"128","author":"Qazilbash","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019120610114119300_B5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-18-0198","article-title":"Autologous lymphocyte infusion supports tumor antigen vaccine-induced immunity in autologous stem cell transplant for multiple myeloma","volume":"7","author":"Cohen","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"2019120610114119300_B6","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2019120610114119300_B7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4238.4238","article-title":"Allogeneic myeloma GVAX with lenalidomide enhances progression free survival through the generation of tumor specific immunity in patients in near complete remission","volume":"126","author":"Borrello","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019120610114119300_B8","doi-asserted-by":"crossref","first-page":"e183267","DOI":"10.1001\/jamaoncol.2018.3267","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial","volume":"4","author":"Nooka","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"2019120610114119300_B9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother"},{"issue":"2","key":"2019120610114119300_B10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"2019120610114119300_B11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2019120610114119300_B12","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2019120610114119300_B13","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/JCO.2016.34.15_suppl.8010","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): final efficacy and safety analysis","volume":"34","author":"Mateos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019120610114119300_B14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"2019120610114119300_B15","author":"US FDA"},{"issue":"8","key":"2019120610114119300_B16","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"issue":"12","key":"2019120610114119300_B17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","article-title":"PD-1 blockade enhances elotuzumab efficacy in mouse tumor models","volume":"1","author":"Bezman","year":"2017","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2019120610114119300_B18","article-title":"Atezolizumab in combination with daratumumab with or without lenalidomide or pomalidomide: a phase Ib study in patients with Multiple Myeloma","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019120610114119300_B19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"16","key":"2019120610114119300_B20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019120610114119300_B21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-014-0043-z","article-title":"Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma","volume":"3","author":"Jing","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2019120610114119300_B22","article-title":"Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy [published online ahead of print March 12, 2019]","author":"Bae","journal-title":"Leukemia"},{"issue":"38","key":"2019120610114119300_B23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/EDBK_205443","article-title":"Practical considerations for antibodies in myeloma","volume":"38","author":"Laubach","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2134","key":"2019120610114119300_B24","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"2019120610114119300_B25","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"2019120610114119300_B26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019120610114119300_B27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-065X.2011.01067.x","article-title":"Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease","volume":"244","author":"Rickert","year":"2011","journal-title":"Immunol Rev"},{"issue":"9","key":"2019120610114119300_B28","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust isolation of malignant plasma cells in multiple myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2019120610114119300_B29","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019120610114119300_B30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"8","key":"2019120610114119300_B31","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"25","key":"2019120610114119300_B32","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019120610114119300_B33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019120610114119300_B34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"2019120610114119300_B35","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019120610114119300_B36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2019120610114119300_B37","article-title":"Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma","volume":"130","author":"Kinneer","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610114119300_B38","article-title":"HDP101, a novel B-cell maturation antigen (BCMA)-targeted antibody conjugated to \u03b1-amanitin, is active against myeloma with preferential efficacy against pre-clinical models of deletion 17p","volume":"132","author":"Singh","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2019120610114119300_B39","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"2019120610114119300_B40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and\/or refractory CD-56-positive multiple myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"102","key":"2019120610114119300_B41","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"2019120610114119300_B42","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","author":"Sherbenou","year":"2016","journal-title":"J Clin Invest"},{"issue":"22","key":"2019120610114119300_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4470.4470","article-title":"SGN-CD48A: a novel humanized anti-CD48 antibody-drug conjugate for the treatment of multiple myeloma","volume":"128","author":"Lewis","year":"2016","journal-title":"Blood"},{"key":"2019120610114119300_B44","author":"Willert","year":"29 -3  2019"},{"issue":"1","key":"2019120610114119300_B45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2019120610114119300_B46","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo [published correction appears in Leukemia. 2017;31(10):2278]","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"2019120610114119300_B47","author":"Topp","year":"31 -4  2019"},{"issue":"suppl 1","key":"2019120610114119300_B48","article-title":"Anti-BCMA BiTE\u00ae AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2019120610114119300_B49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.383.383","article-title":"Preclinical evaluation of a potent anti-Bcma CD3 bispecific molecule for the treatment of multiple myeloma","volume":"128","author":"Panowski","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019120610114119300_B50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2116.2116","article-title":"Development of a new BCMAxCD3 Duobody\u00ae antibody for multiple myeloma","volume":"128","author":"Pillarisetti","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610114119300_B51","article-title":"REGN5458, a bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor efficacy in multiple myeloma models, comparable to that of BCMA CAR T cells","volume":"132","author":"Dilillo","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610114119300_B52","article-title":"Preclinical and nonclinical characterization of HPN217: a tri-specific t cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma","volume":"132","author":"Law","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610114119300_B53","article-title":"Ex vivo assessment of Tnb-383B, a Bcma-bispecific antibody, against primary tumor and endogenous T cells from relapsing multiple myeloma patients","volume":"132","author":"Foureau","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610114119300_B54","article-title":"Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-Directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"issue":"15 suppl","key":"2019120610114119300_B55","doi-asserted-by":"crossref","first-page":"TPS3132","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3132","article-title":"Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed\/refractory multiple myeloma","volume":"36","author":"Richter","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019120610114119300_B56","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019120610114119300_B57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019120610114119300_B58","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"485","key":"2019120610114119300_B59","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"2019120610114119300_B60","article-title":"Serial treatment of relapsed\/refractory multiple myeloma with different BCMA-targeted therapies","author":"Cohen","year":"","journal-title":"Blood Adv"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/266\/1546101\/hem2019000068c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/266\/1546101\/hem2019000068c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:17:33Z","timestamp":1575645453000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/266\/422586\/Myeloma-next-generation-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000068","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}